218 related articles for article (PubMed ID: 32603929)
1. Trend survey on adverse event profiles of antipsychotic long-acting injections and oral agents using the Japanese adverse drug event report database.
Hatano M; Kamei H; Shimato A; Yamada S; Iwata N
Psychiatry Res; 2020 Sep; 291():113249. PubMed ID: 32603929
[TBL] [Abstract][Full Text] [Related]
2. Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics.
Misawa F; Kishimoto T; Hagi K; Kane JM; Correll CU
Schizophr Res; 2016 Oct; 176(2-3):220-230. PubMed ID: 27499361
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports.
Guinart D; Misawa F; Rubio JM; Pereira J; Sharma H; Schoretsanitis G; Kane JM; Correll CU
J Clin Psychiatry; 2020 Nov; 82(1):. PubMed ID: 33238083
[TBL] [Abstract][Full Text] [Related]
4. Risk of discontinuation of antipsychotic long-acting injections vs. oral antipsychotics in real-life prescribing practice: a community-based study.
Verdoux H; Pambrun E; Tournier M; Bezin J; Pariente A
Acta Psychiatr Scand; 2017 May; 135(5):429-438. PubMed ID: 28332704
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia.
Huang CY; Fang SC; Shao YJ
JAMA Netw Open; 2021 May; 4(5):e218810. PubMed ID: 33974056
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics on Time to Rehospitalization Within 1 Year of Discharge in Elderly Patients With Schizophrenia.
Lin CH; Chen FC; Chan HY; Hsu CC
Am J Geriatr Psychiatry; 2020 Jan; 28(1):23-30. PubMed ID: 31481273
[TBL] [Abstract][Full Text] [Related]
7. Risk Factors, Incidence, and Outcomes of Neuroleptic Malignant Syndrome on Long-Acting Injectable vs Oral Antipsychotics in a Nationwide Schizophrenia Cohort.
Guinart D; Taipale H; Rubio JM; Tanskanen A; Correll CU; Tiihonen J; Kane JM
Schizophr Bull; 2021 Oct; 47(6):1621-1630. PubMed ID: 34013325
[TBL] [Abstract][Full Text] [Related]
8. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.
Kishimoto T; Robenzadeh A; Leucht C; Leucht S; Watanabe K; Mimura M; Borenstein M; Kane JM; Correll CU
Schizophr Bull; 2014 Jan; 40(1):192-213. PubMed ID: 23256986
[TBL] [Abstract][Full Text] [Related]
9. Long-Acting Injections in Schizophrenia: a 3-Year Update on Randomized Controlled Trials Published January 2016-March 2019.
Peters L; Krogmann A; von Hardenberg L; Bödeker K; Nöhles VB; Correll CU
Curr Psychiatry Rep; 2019 Nov; 21(12):124. PubMed ID: 31745659
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of long-acting injectable
Vita G; Tavella A; Ostuzzi G; Tedeschi F; De Prisco M; Segarra R; Solmi M; Barbui C; Correll CU
Ther Adv Psychopharmacol; 2024; 14():20451253241257062. PubMed ID: 38831918
[TBL] [Abstract][Full Text] [Related]
11. Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia.
Fang SC; Huang CY; Shao YJ
J Clin Psychiatry; 2022 Jun; 83(4):. PubMed ID: 35649156
[No Abstract] [Full Text] [Related]
12. Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics.
Mahlich J; Olbrich K; Wilk A; Wimmer A; Wolff-Menzler C
Clin Drug Investig; 2021 Jan; 41(1):99-113. PubMed ID: 33331979
[TBL] [Abstract][Full Text] [Related]
13. Long-Acting Injectables Versus Oral Antipsychotics: A Retrospective Bidirectional Mirror-Image Study.
Miura G; Misawa F; Kawade Y; Fujii Y; Mimura M; Kishimoto T
J Clin Psychopharmacol; 2019; 39(5):441-445. PubMed ID: 31415288
[TBL] [Abstract][Full Text] [Related]
14. First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies.
Haddad PM; Taylor M; Niaz OS
Br J Psychiatry Suppl; 2009 Nov; 52():S20-8. PubMed ID: 19880913
[TBL] [Abstract][Full Text] [Related]
15. Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics.
Lin CH; Chen FC; Chan HY; Hsu CC
Int J Neuropsychopharmacol; 2019 Sep; 22(9):541-547. PubMed ID: 31260538
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
[TBL] [Abstract][Full Text] [Related]
17. Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics.
Lin CH; Chan HY; Hsu CC; Chen FC
J Affect Disord; 2021 Jan; 279():292-298. PubMed ID: 33096327
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Long-Acting Injectable Versus Oral Antipsychotics in Patients With Schizophrenia Using the Prevalent New User Design and Subgroup Analyses.
Okada Y; Inada K; Akazawa M
J Clin Psychopharmacol; 2024 May-Jun 01; 44(3):263-271. PubMed ID: 38684048
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of long-acting injectable versus oral antipsychotic drugs in early psychosis: A systematic review and meta-analysis.
Lian L; Kim DD; Procyshyn RM; Fredrikson DH; Cázares D; Honer WG; Barr AM
Early Interv Psychiatry; 2022 Jun; 16(6):589-599. PubMed ID: 34263540
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia.
Fang SC; Liao DL; Huang CY; Hsu CC; Cheng SL; Shao YJ
Hum Psychopharmacol; 2020 May; 35(3):e2729. PubMed ID: 32182388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
